Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694510 | 0.89 | IDO1 (0.56) | IDO1TAAR1ABCB1CHRM2CHRM1 | |
| SCHEMBL1941923 | 0.83 | IDO1 (0.53) | IDO1BCHEACHETAAR1ABCB1 | |
| SCHEMBL8193133 | 0.83 | IDO1 (0.53) | IDO1BCHEACHENPSR1TAAR1 | |
| SCHEMBL5798261 | 0.83 | IDO1 (0.53) | IDO1BCHEACHETAAR1ABCB1 | |
| SCHEMBL7956419 | 0.83 | IDO1 (0.53) | IDO1BCHEACHETAAR1ABCB1 | |
| SCHEMBL2489505 | 0.82 | HTR7 (0.38) | IDO1BCHEACHENPSR1SMN1; SMN2 | |
| SCHEMBL10458199 | 0.82 | IDO1 (0.56) | IDO1BCHEACHETAAR1ABCB1 | |
| SCHEMBL16599934 | 0.81 | IDO1 (0.51) | IDO1BCHEACHETAAR1ABCB1 | |
| SCHEMBL7955176 | 0.81 | IDO1 (0.51) | IDO1BCHEACHETAAR1ABCB1 | |
| Hydrochloric Acid SCHEMBL2473227 | 0.81 | IDO1 (0.54) | IDO1BCHEACHENPSR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280024-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2010-11-04 | — | — | US | disclosed |
| EP-2205559-A1 | RENIN INHIBITORS | Cadila Healthcare Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009087649-A1 | RENIN INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2009-07-16 | — | — | WO | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1776359-A2 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| EP-1707206-A1 | Piperazine derivates for the inhibition of beta-secretase, cathepsin D, plasmepsin ll and HIV protease and for the treatment of malaria, Alzeheimer and AIDS | Speedel Experimenta AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2006005741-A2 | PIPERDINE DERIVATIVES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | REN, AGTR1, ACE | IDO1 4259/4885BCHE 1404/4885ACHE 741/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | IDO1 4691/4885BCHE 168/4885ACHE 416/4885 |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | IDO1 4079/4885BCHE 2152/4885ACHE 598/4885 |
| US-20100280024-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | IDO1 3286/4885BCHE 1189/4885ACHE 524/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | IDO1 3057/4885BCHE 8/4885ACHE 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.